1
|
Viprakasit V, Hamdy MM, Hassab HMA, Sherief LM, Al-Bagshi M, Khattab M, Chuncharunee S, Dung PC, Küpesiz A, Shekhawat A, Sonawane Y, Perez LT, Slader C, Taher AT. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia. Ann Hematol 2023:10.1007/s00277-023-05240-3. [PMID: 37227493 DOI: 10.1007/s00277-023-05240-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 04/17/2023] [Indexed: 05/26/2023]
Abstract
Iron chelation therapy (ICT) is the mainstay of treatment in patients with thalassemia requiring blood transfusions. This phase 2 JUPITER study evaluated patient preference between film-coated tablet (FCT) and dispersible tablet (DT) in transfusion-dependent thalassemia (TDT) or non-TDT (NTDT) patients treated with both formulations in a sequential manner. The primary endpoint was patient-reported preference for FCT over DT, while secondary outcomes included patient reported outcomes (PROs) evaluated by overall preference, and by age, thalassemia transfusion status, and previous ICT status. Out of 183 patients screened, 140 and 136 patients completed the treatment periods 1 and 2 of the core study, respectively. At week 48, the majority of patients preferred FCT over DT (90.3 vs. 7.5%; difference of percentage: 0.83 [95% confidence interval (CI), 0.75-0.89; P < 0.0001]). FCT scored better on secondary PROs and showed less severe gastrointestinal symptoms than DT, except in the change of modified Satisfaction with Iron Chelation Therapy (mSICT) preference scores, which were similar for both the formulations. Patients with TDT had stable ferritin levels, while it showed a downward trend up to week 48 in patients with NTDT on deferasirox treatment. Overall, 89.9% of patients reported ≥ 1 adverse event (AE), of which 20.3% experienced ≥ 1 serious AE. The most common treatment-emergent AEs were proteinuria, pyrexia, urine protein/creatinine ratio increase, diarrhea, upper respiratory tract infections, transaminase increase, and pharyngitis. Overall, this study reinforced the observations from the previous study by showing a distinct patient preference for FCT over DT formulation and further supported the potential benefits of life-long compliance with ICT.
Collapse
Affiliation(s)
- Vip Viprakasit
- Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, 10700, Thailand
| | - Mona M Hamdy
- Clinical Research Center, Cairo University, Cairo, 11562, NA, Egypt
| | - Hoda M A Hassab
- Pediatric Department & Clinical Research Center, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Laila M Sherief
- Faculty of Medicine, Zagazig University, Zagazig Sharqia, 44519, Egypt
| | | | - Mohammed Khattab
- Centre d'Hématologie Et d'oncologie Pédiatrique - CHU Ibn Sina Rabat, 10102, Rabat, Morocco
| | | | - Phu Chi Dung
- Hochiminh City Blood Transfusion Hematology Hospital, Ho Chi Minh City, 700000, Vietnam
| | | | | | - Yamini Sonawane
- Novartis Healthcare Private Limited, Hyderabad, India, 500081
| | | | | | - Ali T Taher
- Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
| |
Collapse
|
2
|
Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Shekhawat A, Jentzsch C, Wiedon A, Behrens F. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial. Arthritis Res Ther 2022; 24:111. [PMID: 35578245 PMCID: PMC9109380 DOI: 10.1186/s13075-022-02797-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 05/03/2022] [Indexed: 11/10/2022] Open
Abstract
Objective To investigate the imaging characteristics and clinically assess heel enthesitis in spondyloarthritis (SpA) by applying in a post hoc analysis the Heel Enthesitis Magnetic Resonance Imaging Scoring system (HEMRIS) in blinded and centrally-read MRI data from the ACHILLES trial (NCT02771210). Methods ACHILLES included patients (≥18 years) with active psoriatic arthritis or axial SpA with clinical and MRI-positive heel enthesitis refractory to standard treatment. Patients were randomized to receive subcutaneous secukinumab 150/300 mg or placebo. At week 24, patients on placebo were switched to secukinumab treatment. MRI-positive heel enthesitis was confirmed in all patients by local investigators. MRIs were performed at 3 timepoints: screening and weeks 24 and 52. In the present analysis, all MRIs were re-evaluated by 2 blinded central readers in a consensus read fashion for a priori defined MRI parameters based on HEMRIS. Results At screening, 171/204 (83.8%) of patients presented with entheseal inflammation and/or structural damage, considering both the Achilles tendon and plantar fascia. Pathologies were more evident in the Achilles tendon area compared to the plantar aponeurosis. The most frequent pathologies were intra-tendon hypersignal and retrocalcaneal bursitis. The mean total entheseal inflammation score at screening in the Achilles tendon area was 2.99 (N=204) and the mean change (standard deviation [SD]) from screening to weeks 24 and 52 was − 0.91 (1.99) and − 0.83 (2.12) in the secukinumab group vs − 0.48 (1.86) and − 0.80 (1.98) in the placebo-secukinumab group, respectively. The mean total structural damage score at screening was 1.36 (N=204) and the mean change (SD) from screening to weeks 24 and 52 was 0.00 (0.65) and − 0.06 (0.56) in the secukinumab group vs 0.08 (0.48) and 0.04 (0.75) in the placebo-secukinumab group, respectively. Conclusions Based on the newly developed HEMRIS, entheseal inflammation and/or structural damage was confirmed in 83.3% of ACHILLES patients. Pathologies were more evident in the Achilles tendon area compared to plantar fascia, with the inflammatory parameters being more responsive with secukinumab treatment compared to placebo. The present analysis, with detailed information on individual MRI parameters, contributes to the scientific debate on heel enthesitis. Trial registration ClinicalTrials.gov NCT02771210. Supplementary Information The online version contains supplementary material available at 10.1186/s13075-022-02797-8.
Collapse
Affiliation(s)
- X Baraliakos
- Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany.
| | - P Sewerin
- Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany.,Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany
| | - E de Miguel
- Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
| | | | | | - A Shekhawat
- Novartis Healthcare Private Limited, Hyderabad, India
| | | | - A Wiedon
- Novartis Pharma GmbH, Nürnberg, Germany
| | - F Behrens
- CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
| | | |
Collapse
|
3
|
Behrens F, Sewerin P, de Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: Results from a Phase 3b trial. Rheumatology (Oxford) 2021; 61:2856-2866. [PMID: 34730795 PMCID: PMC9258542 DOI: 10.1093/rheumatology/keab784] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 10/17/2021] [Indexed: 12/29/2022] Open
Abstract
Objective ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles’ tendon enthesitis in spondyloarthritis (SpA) patients. Methods Patients ≥18 years (n = 204) with active PsA or axial SpA and heel enthesitis were randomized 1:1 to secukinumab 150/300 mg or placebo up to week 24, and thereafter placebo patients were switched to secukinumab. Results At week 24, a higher, yet statistically non-significant (P = 0.136), proportion of patients in secukinumab vs placebo reported resolution of Achilles tendon enthesitis in affected foot (42.2% vs 31.4%; odds ratio [OR] = 1.63; 95% CI: 0.87, 3.08). Proportion of patients reporting resolution of enthesitis based on Leeds Enthesitis Index was higher with secukinumab vs placebo (33.3% vs 23.5%; OR = 1.65; 95% CI: 0.85, 3.25) at week 24. Mean change from baseline in heel pain at week 24 was higher in secukinumab patients vs placebo (−2.8 [3.0] vs −1.9 [2.7]). Greater improvements with secukinumab were observed in heel enthesopathy activity and global assessment of disease activity. Imaging evaluation by local reading confirmed heel enthesitis on MRI at screening for all patients. Based on central reading, 56% presented with bone marrow oedema and/or tendinitis; according to Heel Enthesitis MRI Scoring System (HEMRIS) post hoc analysis, 76% had signs of entheseal inflammation while 86% had entheseal inflammation and/or structural changes. Conclusion A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging assessments of enthesitis requires further investigation. Although ACHILLES did not meet the primary end point, the study reported clinically meaningful improvements in patient-related outcomes. Trial registration clinicaltrials.gov, NCT02771210
Collapse
Affiliation(s)
- Frank Behrens
- CIRI/Rheumatology and Fraunhofer Institute for Translationale Medicine & Pharmacology (ITMP) and Cluster of Excellence Immune-Mediated Diseases (CIMD), Goethe-University, Frankfurt, Germany
| | - Philipp Sewerin
- Department of Rheumatology & Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany
| | - Eugenio de Miguel
- Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
| | - Yusuf Patel
- Hull University Teaching Hospitals, Hull, United Kingdom
| | - Anastas Batalov
- Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria
| | - Eva Dokoupilova
- Medical Plus, s.r.o., Uherske Hradiste; Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Czech Republic
| | | | | | | | | | | | - Xenofon Baraliakos
- Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
| | | |
Collapse
|
4
|
Ueda K, Katayama S, Arai T, Furuta N, Ikebe S, Ishida Y, Kanaya K, Ouma S, Sakurai H, Sugitani M, Takahashi M, Tanaka T, Tsuno N, Wakutani Y, Shekhawat A, Das Gupta A, Kiyose K, Toriyama K, Nakamura Y. Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan. Dement Geriatr Cogn Dis Extra 2019; 9:302-318. [PMID: 31572426 PMCID: PMC6751467 DOI: 10.1159/000501364] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Accepted: 06/05/2019] [Indexed: 01/12/2023] Open
Abstract
Background Few studies have investigated treatment options for patients with Alzheimer's disease (AD) showing a poor response to oral cholinesterase inhibitors (ChEIs) in Japan. Objective To investigate the efficacy and safety of switching from oral ChEIs to rivastigmine transdermal patch in patients with AD. Methods In this multicenter, open-label, phase IV study in outpatient clinics in Japan, patients with mild-moderate AD who had a poor response to or experienced difficulty in continuing donepezil or galantamine were switched to rivastigmine transdermal patch (5 cm2; loaded dose 9 mg, delivery rate 4.6 mg/24 h) with a 1-step titration in week 4 (10 cm2; loaded dose 18 mg, delivery rate 9.5 mg/24 h), which was continued for 4 weeks in the titration period and 16 weeks in a maintenance period. The primary endpoint was the change in Mini-Mental State Examination (MMSE) total score from baseline to week 24. Results A total of 118 patients were enrolled and switched to rivastigmine, of which 102 completed the 24-week study. The MMSE total score was essentially unchanged during the study, with a least-square mean change (SD) of −0.35 (2.64) at week 24 (p = 0.1750). Exploratory analysis with a mixed-effect model comparing changes in MMSE between the pre- and post-switch periods suggested that switching to rivastigmine prevented a worsening of MMSE. Application site skin reactions/irritations occurred in 30.5% of patients overall, in 22.0% in the 8-week titration period, and in 10.2% in the 16-week maintenance period. Conclusion Within-class switching from an oral ChEI to rivastigmine transdermal patch might be an efficacious and tolerable option for AD patients showing a poor or limited response to a prior oral ChEI.
Collapse
Affiliation(s)
| | | | - Tetsuaki Arai
- Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | | | | | | | - Kiyoshi Kanaya
- Hachioji Medical Center, Geriatric Medicine, Tokyo Medical University, Tokyo, Japan
| | - Shinji Ouma
- Department of Neurology, Fukuoka University, Fukuoka, Japan
| | - Hirofumi Sakurai
- Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan
| | | | - Makio Takahashi
- Department of Neurology, Osaka Red Cross Hospital, Osaka, Japan
| | - Toshihisa Tanaka
- Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Norifumi Tsuno
- Department of Neuropsychiatry, Kagawa University School of Medicine, Kagawa, Japan
| | - Yosuke Wakutani
- Department of Neurology, Kurashiki Heisei Hospital, Okayama, Japan
| | - Ankita Shekhawat
- Novartis Healthcare Pvt. Ltd., Data Sciences, SSP, PLS, Hyderabad, India
| | - Ayan Das Gupta
- Novartis Healthcare Pvt. Ltd., Data Sciences, SSP, PLS, Hyderabad, India
| | | | | | - Yu Nakamura
- Department of Neuropsychiatry, Kagawa University School of Medicine, Kagawa, Japan
| |
Collapse
|
5
|
Kahu S, Shekhawat A, Saravanan D, Jugade R. Two fold modified chitosan for enhanced adsorption of hexavalent chromium from simulated wastewater and industrial effluents. Carbohydr Polym 2016; 146:264-73. [DOI: 10.1016/j.carbpol.2016.03.041] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 03/15/2016] [Accepted: 03/16/2016] [Indexed: 10/22/2022]
|
6
|
Abstract
Chitin, a natural amino polysaccharide, has been incorporated with Sn(iv) for effective adsorption of fluoride from water. The material (SnC) was found to be an eco-friendly adsorbent with defluoridation capacity of 14.77 mg g−1.
Collapse
Affiliation(s)
- A. Shekhawat
- Department of Chemistry
- R.T.M. Nagpur University
- Nagpur-440033
- India
| | - S. S. Kahu
- Department of Chemistry
- R.T.M. Nagpur University
- Nagpur-440033
- India
| | - D. Saravanan
- Department of Chemistry
- National College
- Tiruchirappalli-620001
- India
| | - R. M. Jugade
- Department of Chemistry
- R.T.M. Nagpur University
- Nagpur-440033
- India
| |
Collapse
|
7
|
Shekhawat A, Kahu S, Saravanan D, Jugade R. Synergistic behaviour of ionic liquid impregnated sulphate-crosslinked chitosan towards adsorption of Cr(VI). Int J Biol Macromol 2015. [DOI: 10.1016/j.ijbiomac.2015.07.035] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Huang PY, Kurasch S, Alden JS, Shekhawat A, Alemi AA, McEuen PL, Sethna JP, Kaiser U, Muller DA. Imaging Atomic Rearrangements in Two-Dimensional Silica Glass: Watching Silica's Dance. Science 2013; 342:224-7. [DOI: 10.1126/science.1242248] [Citation(s) in RCA: 170] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|